Acrivon Therapeutics (ACRV) Share-based Compensation (2021 - 2026)
Acrivon Therapeutics (ACRV) recorded Share-based Compensation of $2.21 million in Q2 2026, down 43.6% from $3.93 million a year earlier but up 1.5% from the prior quarter.
Powered by 
Analysis
Acrivon Therapeutics (ACRV) Share-based Compensation (2021 - 2026) Analysis & Trends
On a TTM basis, Acrivon Therapeutics' Share-based Compensation came in at $11.4 million as of Jun 30, 2026, down 24.5% year-over-year; for FY2025, it came in at $14.72 million, up 3.0% from FY2024.
- Annual Share-based Compensation has increased for four straight years, with a four-year compound annual growth rate of 133.3% (FY2021 to FY2025).
- Across earlier years, Share-based Compensation came in at $14.29 million in FY2024 (+23.0%), $11.62 million in FY2023 (+431.7%), $2.19 million in FY2022 (+339.6%) and $497,000 in FY2021.
- Quarterly Share-based Compensation has ranged from $40,000 in Q1 2022 to $3.93 million in Q2 2025 over the past five years.
- On a year-over-year basis, Share-based Compensation has declined for three consecutive quarters, with an average decline of 4.7% over the last eight quarters.
- Peak year-over-year performance for Share-based Compensation in the last five years was growth of 441.1% in Q4 2022, against a decline of 43.6% in Q2 2026 at the low end.
- Per Business Quant, the preceding three quarters came in at $2.18 million (Q1 2026), $3.09 million (Q4 2025) and $3.91 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 201.00 Mn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 458.00 Mn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 166.00 Mn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 298.00 Mn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | - |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 165.00 Mn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 231.00 Mn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 249.00 Mn |
| 10 | Acrivon Therapeutics | 76.78 Mn | -358.75 Mn | - | 2.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.21 Mn |
| Mar 31, 2026 | 2.18 Mn |
| Dec 31, 2025 | 3.09 Mn |
| Sep 30, 2025 | 3.91 Mn |
| Jun 30, 2025 | 3.93 Mn |
| Mar 31, 2025 | 3.79 Mn |
| Dec 31, 2024 | 3.71 Mn |
| Sep 30, 2024 | 3.67 Mn |
| Jun 30, 2024 | 3.57 Mn |
| Mar 31, 2024 | 3.34 Mn |
| Dec 31, 2023 | 3.06 Mn |
| Sep 30, 2023 | 3.23 Mn |
| Jun 30, 2023 | 2.69 Mn |
| Mar 31, 2023 | 2.65 Mn |
| Dec 31, 2022 | 1.65 Mn |
| Sep 30, 2022 | 267,000.00 |
| Jun 30, 2022 | 233,000.00 |
| Mar 31, 2022 | 40,000.00 |
| Dec 31, 2021 | 304,000.00 |
| Sep 30, 2021 | 27,000.00 |
API Access
Acrivon Therapeutics Share-based Compensation API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=share-based-compensation&ticker=ACRV&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "share-based-compensation", "ticker": "ACRV", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=share-based-compensation&ticker=ACRV&period=max&api_key=YOUR_API_KEY");
const data = await res.json();